Nomura Holdings Inc. Makes New $341,000 Investment in Insmed Incorporated (NASDAQ:INSM)

Nomura Holdings Inc. acquired a new stake in Insmed Incorporated (NASDAQ:INSM) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 11,010 shares of the biopharmaceutical company’s stock, valued at approximately $341,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Rhumbline Advisers boosted its stake in Insmed by 2.1% during the third quarter. Rhumbline Advisers now owns 197,643 shares of the biopharmaceutical company’s stock worth $4,990,000 after buying an additional 4,081 shares during the period. Federated Hermes Inc. bought a new position in Insmed during the 3rd quarter valued at about $418,000. Northern Trust Corp raised its position in Insmed by 1.7% in the 3rd quarter. Northern Trust Corp now owns 1,346,432 shares of the biopharmaceutical company’s stock worth $33,997,000 after purchasing an additional 21,875 shares during the period. Trexquant Investment LP raised its position in Insmed by 898.8% in the 3rd quarter. Trexquant Investment LP now owns 294,993 shares of the biopharmaceutical company’s stock worth $7,449,000 after purchasing an additional 265,457 shares during the period. Finally, Teza Capital Management LLC bought a new stake in Insmed in the third quarter worth about $368,000.

Insmed Price Performance

Shares of INSM stock opened at $67.99 on Friday. The stock’s 50-day moving average is $38.28 and its 200 day moving average is $31.73. Insmed Incorporated has a 1-year low of $19.68 and a 1-year high of $68.08. The company has a market cap of $10.10 billion, a P/E ratio of -13.00 and a beta of 1.12.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.16. The firm had revenue of $75.50 million during the quarter, compared to the consensus estimate of $77.76 million. The firm’s quarterly revenue was up 15.8% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.17) earnings per share. On average, analysts anticipate that Insmed Incorporated will post -4.5 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on INSM. UBS Group increased their price target on Insmed from $46.00 to $58.00 and gave the stock a “buy” rating in a report on Wednesday, May 29th. Mizuho increased their target price on Insmed from $36.00 to $82.00 and gave the stock a “buy” rating in a research note on Friday, June 7th. Evercore ISI boosted their target price on shares of Insmed from $42.00 to $75.00 and gave the company an “outperform” rating in a research note on Friday. The Goldman Sachs Group raised their price target on shares of Insmed from $49.00 to $74.00 and gave the stock a “buy” rating in a research note on Wednesday, May 29th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Insmed from $55.00 to $72.00 and gave the company an “overweight” rating in a research report on Thursday. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, Insmed presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.38.

Insiders Place Their Bets

In other news, insider Martina M.D. Flammer sold 21,195 shares of the firm’s stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $55.00, for a total value of $1,165,725.00. Following the completion of the sale, the insider now owns 106,134 shares of the company’s stock, valued at approximately $5,837,370. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Martina M.D. Flammer sold 21,195 shares of the stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $55.00, for a total value of $1,165,725.00. Following the completion of the transaction, the insider now directly owns 106,134 shares of the company’s stock, valued at approximately $5,837,370. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO William Lewis sold 22,198 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $25.52, for a total transaction of $566,492.96. Following the sale, the chief executive officer now directly owns 384,125 shares in the company, valued at approximately $9,802,870. The disclosure for this sale can be found here. Over the last three months, insiders have sold 295,842 shares of company stock valued at $13,762,062. 4.60% of the stock is currently owned by insiders.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.